TP53BP1 and cancer: Elucidating the relative contribution of BRCA1–BARD1–related versus unrelated factors for antagonizing 53BP1’s functions could provide critical information on DSB repair pathway choice with implications for using HR and NHEJ in the context of genome editing and for targeting the DDR in cancer therapy.